Literature DB >> 25209313

The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial.

David B Matchar1, Sean R Love, Alan K Jacobson, Robert Edson, Lauren Uyeda, Ciaran S Phibbs, Rowena J Dolor.   

Abstract

Anticoagulation (AC) is effective in reducing thromboembolic events for individuals with atrial fibrillation (AF) or mechanical heart valve (MHV), but maintaining patients in target range for international normalized ratio (INR) can be difficult. Evidence suggests increasing INR testing frequency can improve time in target range (TTR), but this can be impractical with in-clinic testing. The objective of this study was to test the hypothesis that more frequent patient-self testing (PST) via home monitoring increases TTR. This planned substudy was conducted as part of The Home INR Study, a randomized controlled trial of in-clinic INR testing every 4 weeks versus PST at three different intervals. The setting for this study was 6 VA centers across the United States. 1,029 candidates with AF or MHV were trained and tested for competency using ProTime INR meters; 787 patients were deemed competent and, after second consent, randomized across four arms: high quality AC management (HQACM) in a dedicated clinic, with venous INR testing once every 4 weeks; and telephone monitored PST once every 4 weeks; weekly; and twice weekly. The primary endpoint was TTR at 1-year follow-up. The secondary endpoints were: major bleed, stroke and death, and quality of life. Results showed that TTR increased as testing frequency increased (59.9 ± 16.7 %, 63.3 ± 14.3 %, and 66.8 ± 13.2 % [mean ± SD] for the groups that underwent PST every 4 weeks, weekly and twice weekly, respectively). The proportion of poorly managed patients (i.e., TTR <50 %) was significantly lower for groups that underwent PST versus HQACM, and the proportion decreased as testing frequency increased. Patients and their care providers were unblinded given the nature of PST and HQACM. In conclusion, more frequent PST improved TTR and reduced the proportion of poorly managed patients.

Entities:  

Mesh:

Year:  2015        PMID: 25209313     DOI: 10.1007/s11239-014-1128-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  30 in total

1.  Oral anticoagulation and risk of death: a medical record linkage study.

Authors:  Anders Odén; Martin Fahlén
Journal:  BMJ       Date:  2002-11-09

Review 2.  Self-management of oral anticoagulant therapy: a systematic review and meta-analysis.

Authors:  Thomas D Christensen; Søren P Johnsen; Vibeke E Hjortdal; J Michael Hasenkam
Journal:  Int J Cardiol       Date:  2006-08-07       Impact factor: 4.164

3.  Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care.

Authors:  Adam J Rose; Elaine M Hylek; Dan R Berlowitz; Arlene S Ash; Joel I Reisman; Al Ozonoff
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-04-19

Review 4.  Self-monitoring and self-management of oral anticoagulation.

Authors:  Josep M Garcia-Alamino; Alison M Ward; Pablo Alonso-Coello; Rafael Perera; Clare Bankhead; David Fitzmaurice; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

5.  Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation.

Authors:  Adam J Rose; Al Ozonoff; Dan R Berlowitz; Arlene S Ash; Joel I Reisman; Elaine M Hylek
Journal:  Chest       Date:  2011-02-10       Impact factor: 9.410

6.  Effect of home testing of international normalized ratio on clinical events.

Authors:  David B Matchar; Alan Jacobson; Rowena Dolor; Robert Edson; Lauren Uyeda; Ciaran S Phibbs; Julia E Vertrees; Mei-Chiung Shih; Mark Holodniy; Philip Lavori
Journal:  N Engl J Med       Date:  2010-10-21       Impact factor: 91.245

7.  Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study.

Authors:  R H White; S A McCurdy; H von Marensdorff; D E Woodruff; L Leftgoff
Journal:  Ann Intern Med       Date:  1989-11-01       Impact factor: 25.391

8.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

9.  Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.

Authors:  David B Matchar; Gregory P Samsa; Stuart J Cohen; Eugene Z Oddone; Annette E Jurgelski
Journal:  Am J Med       Date:  2002-07       Impact factor: 4.965

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  3 in total

1.  Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.

Authors:  Sutat Kantito; Surasak Saokaew; Sukit Yamwong; Prin Vathesatogkit; Wisuit Katekao; Piyamitr Sritara; Nathorn Chaiyakunapruk
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

2.  At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS).

Authors:  Ciaran S Phibbs; Sean R Love; Alan K Jacobson; Robert Edson; Pon Su; Lauren Uyeda; David B Matchar
Journal:  J Gen Intern Med       Date:  2016-05-27       Impact factor: 5.128

3.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.